Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

Abstract We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination with daratumumab (16 mg/kg per label) and dexamet...

全面介紹

書目詳細資料

Principais autores:	Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, Sascha Tuchman, Christine Chen, Darrell White, Rami Kotb, Heather Sutherland, Michael Sebag, Muhamed Baljevic, William Bensinger, Richard LeBlanc, Chris Venner, Nizar Bahlis, Adriana Rossi, Noa Biran, Heidi Sheehan, Jean‐Richard Saint‐Martin, Dane Van Domelen, Kazuharu Kai, Jatin Shah, Sharon Shacham, Michael Kauffman, Brea Lipe
格式:	Artigo
語言:	Inglês
出版:	Wiley 2021-02-01
叢編:	eJHaem
主題:	Selinexor Multiple Myeloma Daratumumab
在線閱讀:	https://doi.org/10.1002/jha2.122
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!